This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lodise, T. P.
Right arrow Articles by Rybak, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lodise, T. P., Jr.
Right arrow Articles by Rybak, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2007, p. 3731-3733, Vol. 51, No. 10
0066-4804/07/$08.00+0     doi:10.1128/AAC.00101-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Impact of Empirical-Therapy Selection on Outcomes of Intravenous Drug Users with Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus{triangledown}

Thomas P. Lodise Jr.,1* Peggy S. McKinnon,2 Donald P. Levine,3,4 and Michael J. Rybak3,4,5

Albany College of Pharmacy, Albany, New York,1 Barnes-Jewish Hospital, St. Louis, Missouri,2 School of Medicine, Wayne State University, Detroit, Michigan,3 Detroit Receiving Hospital and University Health Center, Detroit, Michigan,4 Anti-Infective Laboratory, College of Pharmacy & Health Sciences, Wayne State University, Detroit, Michigan5

Received 24 January 2007/ Returned for modification 15 March 2007/ Accepted 23 July 2007

This study compares beta-lactam and vancomycin among intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Patients who received vancomycin had higher infection-related mortality, even if they were switched to beta-lactam once culture results became available; this relationship persisted after logistic regression analysis controlling for clinical characteristics.

* Corresponding author. Mailing address: Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208-3492. Phone: (518) 445-7292. Fax: (518) 445-7302. E-mail: lodiset{at}acp.edu

{triangledown} Published ahead of print on 30 July 2007.

Antimicrobial Agents and Chemotherapy, October 2007, p. 3731-3733, Vol. 51, No. 10
0066-4804/07/$08.00+0     doi:10.1128/AAC.00101-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • MacGowan, A. P., on behalf of the BSAC Working Parties on Resistanc, (2008). Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 62: ii105-ii114 [Abstract] [Full Text]  
  • Gqada, Z., Marais, B., Wasserman, E., Bamford, C., Orth, H., Sakoulas, G., Rose, W., Rybak, M. J., Pillai, S., Alder, J., Moellering, R. C. Jr., Eliopoulos, G. M. (2008). Clinical Rationale for Treatment of Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus Developing Nonsusceptibility to Daptomycin. J. Clin. Microbiol. 46: 2471-2472 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»